RUBICON ORGANICS INC (ROMJ.CA) Stock Fundamental Analysis
TSX-V:ROMJ - TSX Venture Exchange - CA78112W1005 - Common Stock - Currency: CAD
Taking everything into account, ROMJ scores 4 out of 10 in our fundamental rating. ROMJ was compared to 35 industry peers in the Pharmaceuticals industry. ROMJ has only an average score on both its financial health and profitability. ROMJ is valued quite expensive, but it does show an excellent growth.
1. Profitability
1.1 Basic Checks
ROMJ had negative earnings in the past year.
In the past year ROMJ had a positive cash flow from operations.
ROMJ had negative earnings in each of the past 5 years.
The reported operating cash flow has been mixed in the past 5 years: ROMJ reported negative operating cash flow in multiple years.
1.2 Ratios
The Return On Assets of ROMJ (-3.60%) is better than 64.86% of its industry peers.
Looking at the Return On Equity, with a value of -5.43%, ROMJ is in the better half of the industry, outperforming 70.27% of the companies in the same industry.
Looking at the Return On Invested Capital, with a value of 21.15%, ROMJ belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -3.6% | ||
| ROE | -5.43% | ||
| ROIC | 21.15% |
ROA(3y)-12.22%
ROA(5y)-20.38%
ROE(3y)-17.4%
ROE(5y)-36.25%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
ROMJ has a Operating Margin of 24.40%. This is amongst the best in the industry. ROMJ outperforms 97.30% of its industry peers.
With an excellent Gross Margin value of 57.91%, ROMJ belongs to the best of the industry, outperforming 89.19% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 24.4% | ||
| PM (TTM) | N/A | ||
| GM | 57.91% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so ROMJ is creating value.
ROMJ has about the same amout of shares outstanding than it did 1 year ago.
The number of shares outstanding for ROMJ has been increased compared to 5 years ago.
ROMJ has a worse debt/assets ratio than last year.
2.2 Solvency
Based on the Altman-Z score of 0.70, we must say that ROMJ is in the distress zone and has some risk of bankruptcy.
ROMJ has a Altman-Z score of 0.70. This is in the better half of the industry: ROMJ outperforms 72.97% of its industry peers.
The Debt to FCF ratio of ROMJ is 24.76, which is on the high side as it means it would take ROMJ, 24.76 years of fcf income to pay off all of its debts.
ROMJ has a Debt to FCF ratio of 24.76. This is in the better half of the industry: ROMJ outperforms 62.16% of its industry peers.
A Debt/Equity ratio of 0.00 indicates that ROMJ is not too dependend on debt financing.
ROMJ has a better Debt to Equity ratio (0.00) than 89.19% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 24.76 | ||
| Altman-Z | 0.7 |
ROIC/WACC2.49
WACC8.49%
2.3 Liquidity
ROMJ has a Current Ratio of 1.57. This is a normal value and indicates that ROMJ is financially healthy and should not expect problems in meeting its short term obligations.
ROMJ's Current ratio of 1.57 is in line compared to the rest of the industry. ROMJ outperforms 51.35% of its industry peers.
A Quick Ratio of 0.97 indicates that ROMJ may have some problems paying its short term obligations.
ROMJ has a Quick ratio (0.97) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.57 | ||
| Quick Ratio | 0.97 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 63.79% over the past year.
The Revenue has grown by 8.20% in the past year. This is quite good.
The Revenue has been growing by 62.28% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)63.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%90.03%
Revenue 1Y (TTM)8.2%
Revenue growth 3Y62.28%
Revenue growth 5YN/A
Sales Q2Q%34.43%
3.2 Future
ROMJ is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 172.55% yearly.
The Revenue is expected to grow by 75.25% on average over the next years. This is a very strong growth
EPS Next Y0%
EPS Next 2Y32.29%
EPS Next 3Y172.55%
EPS Next 5YN/A
Revenue Next Year17.56%
Revenue Next 2Y11.53%
Revenue Next 3Y75.25%
Revenue Next 5YN/A
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
ROMJ reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ROMJ is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, ROMJ is valued cheaply inside the industry as 100.00% of the companies are valued more expensively.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of ROMJ indicates a somewhat cheap valuation: ROMJ is cheaper than 67.57% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 57.18 | ||
| EV/EBITDA | 1.91 |
4.3 Compensation for Growth
A more expensive valuation may be justified as ROMJ's earnings are expected to grow with 172.55% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y32.29%
EPS Next 3Y172.55%
5. Dividend
5.1 Amount
ROMJ does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TSX-V:ROMJ (3/7/2025, 7:00:00 PM)
0.45
+0.02 (+4.65%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners3.89%
Inst Owner ChangeN/A
Ins Owners43.48%
Ins Owner ChangeN/A
Market Cap25.44M
Analysts80
Price Target1.12 (148.89%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-33.33%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)4.78%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 0.57 | ||
| P/FCF | 57.18 | ||
| P/OCF | 11.39 | ||
| P/B | 0.69 | ||
| P/tB | 0.74 | ||
| EV/EBITDA | 1.91 |
EPS(TTM)-0.04
EYN/A
EPS(NY)-0.01
Fwd EYN/A
FCF(TTM)0.01
FCFY1.75%
OCF(TTM)0.04
OCFY8.78%
SpS0.79
BVpS0.65
TBVpS0.61
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -3.6% | ||
| ROE | -5.43% | ||
| ROCE | 29.38% | ||
| ROIC | 21.15% | ||
| ROICexc | 28.58% | ||
| ROICexgc | 31.3% | ||
| OM | 24.4% | ||
| PM (TTM) | N/A | ||
| GM | 57.91% | ||
| FCFM | 1% |
ROA(3y)-12.22%
ROA(5y)-20.38%
ROE(3y)-17.4%
ROE(5y)-36.25%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.8
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 24.76 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 55.7% | ||
| Cap/Sales | 4.02% | ||
| Interest Coverage | 13.63 | ||
| Cash Conversion | 15.88% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.57 | ||
| Quick Ratio | 0.97 | ||
| Altman-Z | 0.7 |
F-Score5
WACC8.49%
ROIC/WACC2.49
Cap/Depr(3y)154.27%
Cap/Depr(5y)259.9%
Cap/Sales(3y)14.55%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)63.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%90.03%
EPS Next Y0%
EPS Next 2Y32.29%
EPS Next 3Y172.55%
EPS Next 5YN/A
Revenue 1Y (TTM)8.2%
Revenue growth 3Y62.28%
Revenue growth 5YN/A
Sales Q2Q%34.43%
Revenue Next Year17.56%
Revenue Next 2Y11.53%
Revenue Next 3Y75.25%
Revenue Next 5YN/A
EBIT growth 1Y13.86%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year72%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y110.22%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y662.22%
OCF growth 3YN/A
OCF growth 5YN/A